Navigation Links
KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
Date:2/26/2013

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) presented data from its Phase 1/2 study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) at the American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Austin, Texas.  The findings demonstrated preliminary safety, tolerability, and signs of activity of anti- GM-CSF antibodies in asthma and support continued development of the company's Humaneered® KB003 anti-GM-CSF monoclonal antibody in severe asthma.  KB003 is currently in a Phase 2 trial in severe asthma patients inadequately controlled by corticosteroids.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

"These initial clinical results with KB002 in asthma are highly encouraging," said Nestor Molfino , Chief Medical Officer of KaloBios.  "KB002 was well-tolerated, with no significant adverse events in the study population.  When KB002 was added to patients' standard of care treatment, the study also showed a reduction in airway inflammation (eosinophils) and improvements in FEV1 (a measure of lung function).  Moreover, asthmatics with reversible FEV1 at baseline showed greater  FEV1 responses than non-reversible patients. As a result, we are targeting this patient population in our ongoing Phase 2 KB003 study."

Methodology and Results

The KB002 Phase 1/2 asthma study, which screened over 50 patients to enroll both atopic (eosinophilic) and non-atopic (neutrophilic) asthma subjects, randomized 24 subjects (2:1, active treatment v
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
4. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
7. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
8. Misonix Presents at MicroCapClub Invitational
9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
10. Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
11. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... in two healthcare conferences during the third quarter, the ... Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation will ... details on each event are below: , ... 2014 in Boston , MA.  The ...
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... , July 29, 2014 New technology ... which could allow physicians to see and assess brain ... promise, according to study authors who released their findings ... th Annual Meeting in Colorado Springs, ... advance the field of neurointervention, a specialty that facilitates ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... Fla., May 08, 2007 /PRNewswire-FirstCall/ --,Viragen, Inc. ... a sponsored in vitro study conducted at ... (multi-,subtype, human alpha interferon) suppressed development of,resistant ... degree than,recombinant alpha interferon. The study has ...
... New Economic Analyses of School and Daycare ... Cost Savings for,Community at Large, TORONTO, May ... research results showing that use of FluMist(R),(Influenza ... school,settings may help reduce the burden of ...
Cached Medicine Technology:Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 2Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 3Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8
(Date:7/29/2014)... a well-known online supplier, now allows worldwide clients to ... by providing graceful and sexy lingerie collection for August. ... sexy dresses , designed and developed by top ... price into consideration. Worry no more, because VogueQueen.com launches ... for all clients. , VogueQueen.com’s top designers sincerely ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that the program ... Alison Freeman wanted to show her patients some alternative ways ... finding out more about this method can easily access it ... currently available in online format. , In the eBook, sufferers ... tips that can help them achieve a cure for herpes. ...
(Date:7/29/2014)... 29, 2014 The Natural Multiple Sclerosis ... inside story to Gary M. Levin’s cure program. ... method for this serious disorder. Levin says that multiple ... that can be found in patients. , Dr. ... For many years, Levin has worked with patients suffering ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica in ... method of naturally overcoming sciatica, in less than 7 ... ensure sufferers that the cure is simple to achieve, ... new method is described as very fast, as it ... 8 minutes per day treatment plan. , Read ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... Highlights: ... - 100% contract renewal for 11 consecutive annual cycles ... initiative acquisition - Diluted earnings per share of ... Service,Corporation (Nasdaq: PRSC ) today announced financial results for the third,quarter ended ...
... cholesterol-busting drugs could be lifesavers, study suggsts , TUESDAY, ... drugs after coronary artery bypass graft (CABG) surgery reduces ... The study, from the Cleveland Clinic, included more than ... late 2005. The overall incidence of post-operative stroke one ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) today announced ... investment activity. "The third quarter was a good ... per share up 8%," commented Douglas M. Pasquale, NHP,s,President ... $150,million of accretive investments, bringing our total for 2007 ...
... Nov. 6 The first annual HealthSaver,Caffeinated ... emerging,health care discount service, found that the ... followed by Tampa, Miami, Phoenix and Atlanta. ... The least caffeinated cities are San Francisco/Oakland, ...
... underperformance and ... deterioration of shareholder value., ANAHEIM, Calif., Nov. ... benefit and pension fund trustees and,administrators are in Anaheim, ... conference. The conference is,considered a premier marketing opportunity for ...
... Research has shown convincing evidence that dietary patterns ... decline and dementia risk. An article published in Annals ... on the benefits of diets high in fruit, vegetables, ... reducing dementia risk. , Adults with diabetes are ...
Cached Medicine News:Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 2Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 3Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 4Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 5Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 6Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 7Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 8Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 9Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 10Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 2Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 3Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 4Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 5Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 6Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 7Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 8Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 9Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 10Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 11Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 12Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 2Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 3Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 4Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 5Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 6Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 7Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: